Stockscreener 앱 받기
0.00
100.00%
-2.27
전일 마감가:
$2.27
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$227.15M
수익:
-
순이익/손실:
$-299.80M
주가수익비율:
0.00
EPS:
-2.84
순현금흐름:
$-217.49M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
명칭
Acelyrin Inc
전화
805-456-4393
주소
4149 LIBERTY CANYON RD., AGOURA HILLS
SLRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
0.00 | 227.15M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.13 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
536.47 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.12 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.94 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-09-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 개시 | H.C. Wainwright | Buy |
| 2023-05-30 | 개시 | Jefferies | Buy |
| 2023-05-30 | 개시 | Morgan Stanley | Overweight |
| 2023-05-30 | 개시 | Piper Sandler | Overweight |
| 2023-05-30 | 개시 | TD Cowen | Outperform |
모두보기
Acelyrin Inc 주식(SLRN)의 최신 뉴스
Acelyrin Requests to Dismiss Class Action Filed by Investors - TradingView
Guggenheim raises Alumis stock to buy with $18 price target By Investing.com - Investing.com Canada
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
Alumis resumed with a Buy at Guggenheim - TipRanks
Guggenheim raises Alumis stock to buy with $18 price target - Investing.com
Jane Street Group LLC Lowers Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Bank of America Corp DE - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Two Sigma Advisers LP - Defense World
Wellington Management Group LLP Invests $567,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
ProShare Advisors LLC Purchases 5,617 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Deutsche Bank AG - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Ameriprise Financial Inc. - Defense World
Alumis resumed with an Overweight at Morgan Stanley - TipRanks
BNP Paribas Financial Markets Invests $236,000 in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Northern Trust Corp Grows Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P TMI Index - marketscreener.com
Acelyrin, Inc.(NasdaqGS: SLRN) dropped from S&P Global BMI Index - marketscreener.com
Alumis completes merger with ACELYRIN, extends cash runway By Investing.com - Investing.com Canada
Alumis completes merger with ACELYRIN, extends cash runway - Investing.com Australia
Alumis Completes Merger With ACELYRIN, Strengthens Pipeline And Cash Runway - Nasdaq
Alumis, Acelyrin Close Merger - marketscreener.com
Alumis Inc. Completes Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Alumis Inc. Completes Merger with ACELYRIN, Inc. to Strengthen Pipeline in Immune-Mediated Disease Therapies - Nasdaq
Alumis completes merger with Acelyrin - TipRanks
Alumis Completes Merger with ACELYRIN - TradingView
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
ACELYRIN Stockholders Approve Merger with Alumis - TipRanks
Alumis Inc. Stockholders Approve Merger with ACELYRIN - TipRanks
Dimensional Fund Advisors LP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
Alumis Stockholders Approve Merger with ACELYRIN - The Manila Times
Alumis wins shareholder nod for ACELYRIN merger - Investing.com
ACELYRIN shareholders approve Alumis merger deal - Investing.com
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
Alumis-ACELYRIN Merger Gets Green Light: Major Breakthrough for Immune Disease Treatment Pipeline - Stock Titan
Hsbc Holdings PLC Makes New $36,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (SLRN) Projected to Post Earnings on Tuesday - Defense World
Barclays PLC Increases Stock Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Wells Fargo & Company MN Grows Holdings in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin Inc (SLRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.47%
자본화:
|
볼륨(24시간):